See other companies on Welcome to the Jungle
uMotif
Data capture platform for clinical trials
- 21-100 employees
- Healthcare
- B2B
- Market research
- SaaS
- MedTech
- South Bank, London, UK
Jump to section
Company mission
To engage patients in order to capture data to support their healthcare and research journey.
-20% employee growth in 12 months
Our take
For over a decade now, uMotif has been helping make clinical trials faster, easier, and more reliable. The uMotif app allows participants to record data themselves remotely, instead of travelling to a centralised location - be that through wearables, electronic assessment, or self-report.
This positions uMotif as one of the older decentralised trial tech startups, and it’s helped the company get a good head start in building a global presence. That said, this may not insulate uMotif for long in an increasingly crowded market, with many well-funded, high performing platforms offering the same kind of tech - including SnapIOT, Medable and Clinical Ink.
Demand, however, is likely to be high for the winning players. Decentralised trial monitoring is here to stay, and tech-accelerated pharmaceutical developments means the market is expected to grow substantially going forwards. Recently, uMotif has focussed on securing partnerships with other tech players to bring heightened value to its offerings, and has showcased its popularity with a Best of Show win at the 2023 SCOPE Summit for Clinical Ops Executives.
Steph
Company Specialist at Welcome to the Jungle
Benefits
- Remote working solutions
- Unlimited PTO allowance
- 401(k) Retirement Plan contribution
- Majority company funded Health / Dental / Vision plans
Company values
- Patients First - We care about patients and put them first; from our products to our business decisions
- Teamwork - Through collaborating with and supporting each other, our customers, and our partners we succeed together
- Innovation - We work innovatively to design, build, and deliver engaging technology
Funding (last 2 of 7 rounds)
May 2022
$25.5m
LATE VC
Sep 2020
$7.6m
SERIES A
Total funding: $38m
Leadership
Bruce Hellman
(Chief Patient Officer)Held various policy and strategy roles at the UK Department for Culture, Media and Sport, then pivoted to management consultancy with Serco.
Ben James
(Chief Design Officer)Worked as a consultant for interaction design and development at Schematic and ico Design Consultancy, also serving as director of Highrise Design for over a decade.